CPT code 64624 represents neurolytic ablation of branches of the genicular nerves supplying the knee joint using chemical, heat, or radiofrequency agents, with imaging guidance included when performed. This procedure is an important option in the interventional management of chronic knee pain, particularly for patients who are poor candidates for or wish to delay joint replacement. Nationally, coverage, utilization, and payment policies for genicular nerve procedures have grown as evidence for targeted nerve ablation has expanded and minimally invasive pain-management strategies have gained prominence.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical intent and service settings, standard billing considerations tied to the CPT descriptor, and the types of benchmarks typically used to compare utilization and reimbursement across major payers. The publication also outlines common reporting practices, coding boundaries (for example, imaging guidance included), and context for how this procedure fits within broader interventional pain and orthopedic care pathways.

This summary is written for a national audience and provides clinicians, billing professionals, and policy analysts a concise reference to the clinical purpose of CPT code 64624, the likely sites of service, and the payer landscape relevant to adoption and coverage discussions.